Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic - touchONCOLOGY

touchIN CONVERSATION for touchONCOLOGY Listen to Prof. John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) in conversation with Dr Raajit Rampal (Memorial Sloan Kettering Cancer Center, New York, NY, USA) on how to optimize the use of JAK inhibitors for patients with myelofibrosis.  They respond to questions submitted by the HCP audience and provide expert insights on:  The key considerations when selecting a first-line JAK inhibitor  How to best manage side effects associated with JAK inhibitors The treatment options following failure on a first-line JAK inhibitor This touchPODCAST is for HCPs only.  This activity is funded by an unrestricted independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/in-conversation-jak-inhibition-in-myelofibrosis